Replies to post #9962 on BioCurex, Inc.(fka BOCX)

[HALF FULL GLASS]

At BioCurex, studies using breast, gastric and other types of cancers (n= 68) and normal samples (n=52) had an area under the curve (AUC) for the ROC curve of 0.954 with a cancer/normal ratio of 1.7. Initial experiments at Abbott Laboratories with prostate cancer (n=8) and non cancer samples (n=16) had AUC for ROC curve of 0.95 with a C/N ratio of 1.3.

Conclusions: We developed a non-radioactive RECAF CIA assay that separates multiple types of cancer from normal
sera with a C/N ratio ranging from 1.3 to 1.7. Our future studies will focus on increasing the cancer/normal ratio to create a manufacturable RECAF CIA assay.